chemo Flashcards
MOA: 5-FU
pyrimidine analogue
MOA: alemtuzumab
targets CD52
MOA: axitinib
TKI
MOA: azathioprine
purine analogue
MOA: bevacizumab
VEGF-A inhibitor
MOA: bleomycin
binds DNA (causing strand breaks? - exact action unknown)
MOA: bortezomib
protease inhibitor
MOA: brentuximab
targets CD30
MOA: busulfan
alkylating agent
MOA: capecitabine
prodrug for 5-FU (pyrimidine analogue)
MOA: cabazitaxel
taxane (microtubule stabilizer)
MOA: carboplatin
cross-links DNA
MOA: carmustine
alkylating agent (notrosourea)
MOA: cetuximab
EGFR inhibitor
MOA: cisplatin
cross-links DNA
MOA: cobimetinib
MEK inhibitor
MOA: crizotinib
inhibits ALK and ROS1
MOA: cyclophosphamide
alkylating agent (nitrogen mustard)
MOA: cytrarabine / ara-c
pyrimidine analogue
MOA: dabrafenib
BRAF inhibitor
MOA: dacarbazine
alkylating agent
MOA: dasatinib
Bcr-Abl TKI
MOA: docetaxel
taxane (microtubule stabilizer)
MOA: doxorubicin
DNA intercalation
MOA: epirubicin
DNA intercalation
MOA: erlotinib
EGFR inhibitor
MOA: etanercept
inhibits TNF-alpha
MOA: etoposide
topoisomerase inhibitor
MOA: everolimus
mTOR inhibitor
MOA: fludarabine
purine analogue
MOA: gefitinib
EGFR inhibitor
MOA: gemcitabine
pyrimidine analogue
MOA: idelalisib
PI3K inhibitor
MOA: ifosfamide
alkylating agent (nitrogen mustard)
MOA: imatinib
Bcr-Abl TKI
MOA: infliximab
inhibits TNF-alpha
MOA: ipilimumab
targets CTLA-4
MOA: irinotecan
topoisomerase inhibitor
MOA: lenalidomide
derivative of thalidomide, mechanism unknown
MOA: leucovorin / folinic acid
inhibits thymidylate synthase
MOA: lomustine
alkylating agent (notrosourea)
MOA: melphalan
alkylating agent (nitrogen mustard)
MOA: mercaptopurine
purine analogue
MOA: methotrexate
inhibits dihydrofolate reductase
MOA: mitomycin
cross-links DNA
MOA: nivolumab
PD1 inhibitor
MOA: oxaliplatin
cross-links DNA
MOA: paclitaxel
taxane (microtubule stabilizer)
MOA: panitumumab
EGFR inhibitor
MOA: pazopanib
multikinase TKI
MOA: pembrolizumab
PD1 inhibitor
MOA: pemetrexed
inhibits thymidylate synthase and dihydrofolate reductase
MOA: pertuzumab
targets HER2
MOA: rituximab
targets CD20
MOA: sirolimus
mTOR inhibitor
MOA: sorafenib
multikinase TKI
MOA: sunitinib
multikinase TKI
MOA: tacrolimus
calcineurin inhibitor
MOA: temozolomide
alkylating agent
MOA: temsirolimus
mTOR inhibitor
MOA: topotecan
topoisomerase inhibitor
MOA: trametinib
MEK inhibitor
MOA: trastuzumab
targets HER2
MOA: vemurafenib
BRAF inhibitor
MOA: vinblastine
disrupts microtubules (vinca alkaloid)
MOA: vincristine
disrupts microtubules (vinca alkaloid)